4.3 Article

MiR-23a modulates X-linked inhibitor of apoptosis-mediated autophagy in human luminal breast cancer cell lines

Journal

ONCOTARGET
Volume 8, Issue 46, Pages 80709-80721

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.21080

Keywords

miR-23a; autophagy; XIAP; breast cancer

Funding

  1. National Nature Science Foundation of China [81472493, 81572305, 81372476]
  2. Anhui Medical University [2013xkj006]
  3. Anhui provincial academic and technical leader reserve candidate [2016H074]
  4. Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui [gxyqZD2016046]
  5. Second affiliated Hospital of Anhui Medical University [2014KA02]

Ask authors/readers for more resources

Autophagy is a conserved multi-step lysosomal process that is induced by diverse stimuli including cellular nutrient deficiency. X-linked inhibitor of apoptosis (XIAP) promotes cell survival and recently has been demonstrated to suppress autophagy. Herein, we examined regulation of XIAP-mediated autophagy in breast cancer cells and determined the underlying molecular mechanism. To investigate this process, autophagy of breast cancer cells was induced by Earle's balanced salt solution (EBSS). We observed discordant expression of XIAP mRNA and protein in the autophagic process induced by EBSS, suggesting XIAP may be regulated at a post-transcriptional level. By scanning several miRNAs potentially targeting XIAP, we observed that forced expression of miR-23a significantly decreased the expression of XIAP and promoted autophagy, wherever down-regulation of miR-23a increased XIAP expression and suppressed autophagy in breast cancer cells. XIAP was confirmed as a direct target of miR-23a by reporter assay utilizing the 3'UTR of XIAP. In vitro, forced expression of miR-23a promoted autophagy, colony formation, migration and invasion of breast cancer cell by down-regulation of XIAP expression. However, miR-23a inhibited apoptosis of breast cancer cells independent of XIAP. Xenograft models confirmed the effect of miR-23a on expression of XIAP and LC3 and that miR-23a promoted breast cancer cell invasiveness. Therefore, our study demonstrates that miR-23a modulates XIAP-mediated autophagy and promotes survival and migration in breast cancer cells and hence provides important new insights into the understanding of the development and progression of breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Lipidomic Perturbations in Cynomolgus Monkeys are Regulated by Thyroid Stimulating Hormone

Tao Xu, Yanling Yang, Xing Huang, Jianhong Ren, Ting Xu, Wei Xie

Summary: Thyroid disease affects approximately 200 million people worldwide and is often associated with elevated blood lipid levels. A study on cynomolgus monkeys revealed that the changes in TSH and T3/T4 levels were correlated with lipid accumulation, with perturbations in numerous lipid species. The administration of SNA001 showed comparable effects on TSH, T3/T4 levels, and lipid profiles as the reference rhTSH (Thyrogen(R)), indicating a need for further exploration into the delayed responses observed in lipid levels after TSH stimulation.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Article Oncology

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy

Enliang Li, Xing Huang, Gang Zhang, Tingbo Liang

Summary: This study systematically investigated the potential effectiveness of a novel pancreatic cancer immunotherapy targeting RTKs, and revealed the function of MET in PD-L1 regulation as well as the combined therapeutic efficacy of MET and PD-L1 in pancreatic cancer. Results showed that MET is a pancreatic cancer-specific RTK significantly associated with prognosis and positively correlated with PD-L1 levels. The study also demonstrated that MET deficiency facilitates lymphocyte infiltration into pancreatic tumors and verified significant benefits of combining MET inhibition with PD-1/PD-L1 blockage in mouse models of pancreatic cancer.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Article Multidisciplinary Sciences

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1

Xiaozhen Zhang, Xing Huang, Jian Xu, Enliang Li, Mengyi Lao, Tianyu Tang, Gang Zhang, Chengxiang Guo, Xiaoyu Zhang, Wen Chen, Dipesh Kumar Yadav, Xueli Bai, Tingbo Liang

Summary: The study reveals that NEK2 phosphorylates PD-L1 to maintain stability, impacting the efficacy of immunotherapy in pancreatic cancer, while NEK2 deficiency enhances lymphocyte infiltration and sensitivity to immunotherapy. Inhibiting NEK2 can enhance PD-L1 blockade, potentially improving the effectiveness of pancreatic cancer treatment.

NATURE COMMUNICATIONS (2021)

Article Oncology

Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell

Xing Huang, Gang Zhang, Tingbo Liang

Summary: The lack of the TGFB signaling pathway in CD4(+) helper T cells induces remodeling of intratumoral vascular tissue, preventing tumor cells from receiving necessary nutrients and ultimately causing tumor cell death due to starvation. Blocking TGFB promotes tissue healing, leading to an effective anticancer immune response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis

Yu-ting Shen, Xing Huang, Gang Zhang, Bo Jiang, Cheng-jun Li, Zheng-sheng Wu

Summary: ERα, ERβ, and PGR proteins were found to be differentially expressed in ovarian and uterine cancers, correlating with tumor stage and grade. In addition, the mRNA expression levels of ESR1, ESR2, and PGR were significantly associated with immunomodulators and immune cells. This suggests that ESR1, ESR2, and PGR could serve as potential prognostic markers and therapeutic targets for various cancers.

FRONTIERS IN ONCOLOGY (2021)

Review Medicine, General & Internal

Combined targeted therapy and immunotherapy for cancer treatment

Cheng-Xiang Guo, Xing Huang, Jian Xu, Xiao-Zhen Zhang, Yi-Nan Shen, Ting-Bo Liang, Xue-Li Bai

Summary: This review summarizes the recent combinations of targeted therapies and immunotherapies, highlighting the synergistic effects on anti-tumor immunity for rapid tumor regression and durable response, while also addressing the associated clinical challenges.

WORLD JOURNAL OF CLINICAL CASES (2021)

Review Oncology

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Lingyue Liu, Xing Huang, Fukang Shi, Jinyuan Song, Chengxiang Guo, Jiaqi Yang, Tingbo Liang, Xueli Bai

Summary: Pancreatic cancer has a high mortality rate and immunotherapy with anti-PD-(L)1 has limited efficacy. This review explores the combination of chemotherapy, radiotherapy, targeted therapy, and immunotherapy with anti-PD-(L)1 in pancreatic cancer treatment. It also suggests future directions for optimizing combination therapy.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Review Pharmacology & Pharmacy

Subtyping for pancreatic cancer precision therapy

Xing Huang, Gang Zhang, Tingbo Liang

Summary: The cases and deaths related to pancreatic cancer are on the rise globally, posing a significant global health concern. The heterogeneous nature of pancreatic cancer within and between tumors has been identified as a critical factor contributing to its poor prognosis. However, there is a lack of precise management strategies for this complex disease. Subtyping pancreatic tumors based on their molecular characteristics shows promise in improving the accuracy of treatment decisions, but its feasibility and potential flaws need further exploration.

TRENDS IN PHARMACOLOGICAL SCIENCES (2022)

Article Oncology

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis

Tianyu Tang, Xing Huang, Gang Zhang, Minghao Lu, Zhengtao Hong, Meng Wang, Junming Huang, Xiao Zhi, Tingbo Liang

Summary: This study demonstrates that LTX-315 can enhance lymphocyte infiltration and induce an antitumor immune response by inhibiting PD-L1 expression in pancreatic tumors. ATP11B is identified as a potential target of LTX-315 and a critical regulator in maintaining PD-L1 expression.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity

Tianyu Tang, Xing Huang, Gang Zhang, Tingbo Liang

Summary: Oncolytic peptides are highly effective in remodeling the tumor microenvironment and enhancing anticancer immunity by inducing immunogenic cell death. A recent study shows that LTX-315 inhibits PD-L1 expression via ATP11B, thereby enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. This commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, as well as the potential issues and directions in cancer immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Multidisciplinary Sciences

Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner

Tianyu Tang, Xing Huang, Minghao Lu, Gang Zhang, Xu Han, Tingbo Liang

Summary: Cancer cell metabolism and immunosuppressive tumor microenvironment are influenced by the aberrant expression of CD73. CD73 facilitates the recruitment of Treg cells to pancreatic tumors, leading to an immunosuppressive microenvironment. CD73 transcriptionally upregulates CCL5 through tumor cell-autocrine adenosine-Adora2a signaling-mediated activation of the p38-STAT1 axis. This study highlights the importance of CD73-adenosine metabolism in pancreatic cancer immunosuppression in a tumor-autonomous and -autocrine manner.

NATURE COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial

Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Junhui Sun, Wenbo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xueli Bai, Tingbo Liang

Summary: A study found that preoperative drug-eluting bead transarterial chemoembolization (DEB-TACE) plus sintilimab could be an effective treatment approach before surgery for patients with HCC of BCLC stage A exceeding the Milan criteria or BCLC stage B.

HEPATOLOGY COMMUNICATIONS (2023)

Review Biochemistry & Molecular Biology

mRNA vaccines in disease prevention and treatment

Gang Zhang, Tianyu Tang, Yinfeng Chen, Xing Huang, Tingbo Liang

Summary: mRNA vaccines have shown remarkable efficacy in preventing and treating diseases, particularly in the case of COVID-19. This comprehensive review examines the technical aspects of mRNA vaccines, including design, synthesis, delivery, and adjuvant technologies. It provides a systematic analysis of representative mRNA vaccines used in various diseases and explores their potential in different therapeutic areas. The review also discusses current challenges and future directions for the advancement and utilization of mRNA vaccines.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Review Medicine, General & Internal

Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

Xing Huang, Gang Zhang, Tian Yu Tang, Xiang Gao, Ting Bo Liang

Summary: Pancreatic cancer vaccines offer multifaceted advantages, with personalized mRNA vaccines showing promising potential as a cutting-edge option for precise treatment. Further research and development in this area is warranted.

MILITARY MEDICAL RESEARCH (2022)

Article Medicine, General & Internal

mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Tian-Yu Tang, Xing Huang, Gang Zhang, Ming-Hao Lu, Ting-Bo Liang

Summary: Cholangiocarcinoma is a highly aggressive tumor that currently lacks effective treatment options. A recent study has proposed an immunotherapeutic strategy using mRNA vaccines, with a focus on selecting suitable patients and identifying potent antigens. However, further research is needed to better understand the immunogenic antigens and onco-immunological characteristics of cholangiocarcinoma for future clinical applications.

MILITARY MEDICAL RESEARCH (2022)

No Data Available